First Patient Treated With ILB in TIKOMED's Clinical Trial for ALS

First Patient Treated With ILB in TIKOMED's Clinical Trial for ALS

Press Release (ePRNews.com) - VIKEN, Sweden - Nov 02, 2018 - TIKOMED, a specialty pharmaceutical company focused on developing therapeutics for treating acute and degenerative neurological diseases, announce today that the first patient with Amyotrophic Lateral Sclerosis (ALS) has been treated with the company’s investigational drug ILB, in the on-going clinical trial at Sahlgrenska University Hospital in Gothenburg, Sweden.

Anders Svenson M.D., Chief Medical Officer of TIKOMED, commented, “We are very pleased that our clinical trial, with our investigational drug ILB for the treatment of ALS, is well underway and that the trial’s first patient has successfully completed the four-week treatment period with ILB. We believe this clinical trial, conducted at Sahlgrenska University Hospital, will demonstrate the safety and tolerability of ILB in the treatment of ALS.”

With Dr. Lennart Persson as principal investigator, the clinical trial is conducted at and in collaboration with Sahlgrenska University Hospital in Gothenburg. 15 patients with ALS will receive ILB for a four-week treatment period followed by a three-month, follow-up period.

Anders Kristensson, Chief Executive Officer of TIKOMED, commented, “With ILB we present a potentially new class of drug which can address the underlying causes of neurodegeneration, as seen in a chronic disease such as ALS. We are committed to bringing ILB through our ALS clinical trial program and hopefully one step closer to ALS sufferers battling this fatal disease.”

TIKOMED will also be running a phase II ALS study in collaboration with Birmingham University in Birmingham, UK. In this trial, 15 patients with ALS will receive ILB for a ten-week treatment period.

Source : TIKOMED AB
SHARE :  
Business Info :
TikoMed AB

You may also like this  

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or Signup using Email

Already have an account ? Login

Reset Password

Already have an account ? Login

DISCLAIMER

If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/ services/ business mentioned and hereby disclaims any content contained in this press release.